Projekt
BIOMASTER BIOMONITOR III
Abgeschlossen · 2020 bis 2022
Ammann Peter, Schneider Irene
Art
Reichweite
Bereiche
Status
Start
Ende
Finanzierungsart
Studiendesign
Kurzbeschreibung/Zielsetzung
This study is a post-market clinical follow-up (PMCF) study to identify and evaluate residual risks associated with the use of the BIOMONITOR III that are discovered or remain even after risk analysis, risk mitigation and successful conformity assessment. Furthermore, this study will also provide additional data as required by regulatory authorities outside of the CE-region.
Primary endpoint
SADE-free rate related to BIOMONITOR III including incision and insertion tool set until 3-month follow-up